VRTX's core small-molecule franchise has sustained gross margins in a tight 84.7% to 86.9% band across ten quarters, and revenue growth near 11.8% year over year suggests the commercial base remains durable.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew from roughly $2.6B to $3.4B over the period with a stable ~85% gross margin, but operating margin swung from 40.3% in 2025Q4 to 20.7% in 2026Q3, suggesting cost pressures that warrant monitoring.
Vertex invests in scientific innovation to create transformative medicines for serious diseases, focusing on discovering and developing innovative treatments.
Vertex was one of the first biotech firms to use rational drug design, establishing a strong reputation in the biopharmaceutical industry.
There is a bullish thesis on Vertex Pharmaceuticals, indicating positive investor sentiment and potential upside for the stock.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 2, 2026 | $4.76-1.2% vs $4.82 | $3.4B+0.6% vs $3.4B |
Q3 2026 Aug 3, 2026 | $4.73-0.2% vs $4.74 | $3.3B+3.2% vs $3.2B |
Q2 2026 May 4, 2026 | $4.47+5.4% vs $4.24 | $3.0B-0.2% vs $3.0B |
Q1 2026 Feb 12, 2026 | $5.03-1.6% vs $5.11 | $3.2B+0.2% vs $3.2B |
Vertex Pharmaceuticals' moat in cystic fibrosis remains nearly impregnable. The company's diversification efforts are slowly ramping up, and more is to come.
Associated Banc Corp acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,962 shares of the pharmaceutical company's stock, valued at approximately $3,117,000. A number of other hedge funds
AIA Group Ltd reduced its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 23.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,080 shares of the pharmaceutical company's stock after selling 7,521 shares during the period. AIA Group Ltd's holdings
VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.
Benchmark VRTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Vertex Pharmaceuticals Incorporated (VRTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $547.09 | $138.85B | 35.12 | 9.57% | 30.61% | 20.08% | — | |
| $904.35 | $93.17B | 19.82 | 0.99% | 28.51% | 15.07% | 0.38% | |
| $155.94 | $20.82B | 7.90 | 65.19% | 54.34% | 159.72% | — | |
| $56.03 | $10.83B | -567.68 | 12.87% | -0.52% | -0.31% | — | |
| $17.82 | $1.88B | 127.93 | 15.58% | 0.75% | 1.04% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — |
Vertex Pharmaceuticals Incorporated (VRTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Vertex Pharmaceuticals Incorporated (VRTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 2, 2026·SEC
Oct 20, 2026·SEC
Aug 3, 2026·SEC
Get notified when VRTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vertex Pharmaceuticals Incorporated (VRTX) stock FAQ — growth, dividends, profitability & financials explained
Vertex Pharmaceuticals Incorporated (VRTX) reported $12.99B in revenue over the trailing twelve months. Revenue was $12.07B in fiscal year 2025. That is 90686% more than the $13.3M of fiscal year 1996.
Vertex Pharmaceuticals Incorporated (VRTX) grew revenue by 10.8% over the trailing twelve months, compared with the twelve months before.
Yes. Vertex Pharmaceuticals Incorporated (VRTX) earned $3.98B in net income over the trailing twelve months (a 30.6% net margin).
Vertex Pharmaceuticals Incorporated (VRTX) had a return on equity (ROE) of 20.1% over the trailing twelve months. That is well above the market's typical 10-15%.
Vertex Pharmaceuticals Incorporated (VRTX) generated $3.20B in free cash flow over the trailing twelve months.
